论文部分内容阅读
目的探讨肿瘤干细胞标志物CD133在结直肠癌组织中的表达,及其与临床病理因素、survivin和Ki67的关系。方法应用免疫组织化学方法检测60例手术切除的结直肠癌和30例癌旁组织及12例正常组织中CD133的表达、癌组织中survivin和Ki67的表达,对各指标之间的相关关系及其与性别、年龄、肿瘤的部位和大小、病理分级、侵袭深度、淋巴结转移、pTNM分期之间的关系进行分析。结果结直肠癌组织中CD133阳性表达率为50%(30/60),显著高于癌旁及正常组织(P<0.01);CD133的表达与淋巴结转移和pTNM分期密切相关(P<0.01),与病理分级存在相关性(P<0.05),与其他临床病理因素均无关;survivin的表达仅与肿瘤的病理分级相关(P<0.05),Ki67与各项临床病理参数均无相关性;CD133与survivin、Ki67的表达呈正相关(P<0.05、P<0.01);survivin与Ki67的表达呈正相关(P<0.01)。结论结直肠癌组织中存在CD133+肿瘤细胞,肿瘤干细胞在结直肠癌的发生、发展中起重要作用,检测肿瘤干细胞标志物CD133的表达可作为一种判断肿瘤的恶性程度和预后的重要指标。
Objective To investigate the expression of tumor stem cell marker CD133 in colorectal cancer and its relationship with clinicopathological factors, survivin and Ki67. Methods The expressions of CD133, survivin and Ki67 in 60 cases of resected colorectal cancer, 30 cases of paracancerous tissues and 12 cases of normal tissues were detected by immunohistochemistry. The correlations among the above indexes The relationship was analyzed with gender, age, tumor location and size, pathological grade, invasion depth, lymph node metastasis and pTNM staging. Results The positive rate of CD133 in colorectal cancer tissues was 50% (30/60), which was significantly higher than that in adjacent normal tissues and normal tissues (P <0.01). The expression of CD133 was closely related to lymph node metastasis and pTNM stage (P <0.01) (P <0.05), and had no correlation with other clinicopathological factors; the expression of survivin was only correlated with the pathological grade of tumor (P <0.05); Ki67 had no correlation with various clinical and pathological parameters; the expression of CD133 and survivin , Ki67 (P <0.05, P <0.01). There was a positive correlation between the expression of Ki67 and survivin (P <0.01). Conclusion CD133 + tumor cells exist in colorectal cancer tissues. Cancer stem cells play an important role in the occurrence and development of colorectal cancer. Detecting the expression of tumor stem cell marker CD133 can be used as an important index to judge the malignant degree and prognosis of colorectal cancer.